According to an announcement from CStone Pharma-B (02616), the company was informed by Dr. Yang Jianxin that between September 17 and 22, 2026, he purchased a total of 496,000 shares in the open market using personal funds, with a total consideration exceeding HK$2.7 million.

The board of directors believes that this share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.

Since assuming the role of Chief Executive Officer in August 2022, Dr. Yang has accumulated a total of 14,210,500 shares in the open market.

Following the share purchase, Dr. Yang holds shares representing approximately 5.31% of the company's total issued share capital as of the date of this announcement.

The latest clinical data for the company's core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Annual Congress in October 2026.

Dr. Yang stated that he is full of confidence in the company's long-term investment value and core competitive advantages.

Dr. Yang does not rule out the possibility of further increasing his shareholding in the company at an appropriate time.